Topics
Glioblastoma | Treatment | Clinical trials | Temozolomide
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Temozolomide
Bhaskaran D, Savage J, Patel A,
Collinson F, Mant R, Boele F, Brazil L, Meade S, Buckle P, Lax S,
Billingham L, Short SC.
A
randomised phase II trial of temozolomide with or without
cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT):
protocol for a multi-centre, double-blind, placebo-controlled
trial.
BMC
Cancer. 2024 Jan
15;24(1):83. doi:
10.1186/s12885-023-11792-4. PMID:
38225549. Interventional
study protocol. ˍ
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto
Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama
Y, Miyake K, Sasaki H.
An exploratory
prospective phase II study of preoperative neoadjuvant bevacizumab
and temozolomide for newly diagnosed glioblastoma.
J
Neurooncol. 2024 Jan 31. doi:
10.1007/s11060-023-04544-8. PMID:
38291182. Interventional
study. ˍ
Anvari K, Seilanian Toussi M, Saghafi M, Javadinia SA, Saghafi H,
Welsh JS.
Extended dosing (12 cycles)
vs conventional dosing (6 cycles) of adjuvant temozolomide in
adults with newly diagnosed high-grade gliomas: a randomized,
single-blind, two-arm, parallel-group controlled trial.
Front
Oncol. 2024 May 7;14:1357789. doi:
10.3389/fonc.2024.1357789. PMID:
38774410. Interventional
study. ˍ